Alkem LaboratoriesNSE:ALKEM -0.04%96 Days Payable is 164.10 as of Mar. 2026, which is 57% above its 10-year median of 104.66. GuruFocus rates NSE:ALKEM with a GF Score™ of 96/100 and a GF Value™ of ₹6,078.06 (Fairly Valued). The stock has 1 warning sign investors should review. Among 922 Drug Manufacturers companies, Alkem Laboratories ranks better than 72.45% on this metric.
The historical rank and industry rank for Alkem Laboratories's Days Payable or its related term are showing as below:
NSE:ALKEM'
s Days Payable Range Over the Past 10 Years
Min: 85.65 Med: 104.66 Max: 146.33
Current: 142.63
During the past 13 years, Alkem Laboratories's highest Days Payable was 146.33. The lowest was 85.65. And the median was 104.66.
NSE:ALKEM's Days Payable is ranked better than 72.45% of 922
companies
in the Drug Manufacturers industry
Industry Median: 90.835
vs NSE:ALKEM: 142.63
Alkem Laboratories's Days Payable
increased
from Mar. 2025 (131.20) to Mar. 2026 (164.10).
It may suggest that Alkem Laboratoriesdelayed paying its suppliers.
Alkem Laboratories Days Payable Related Terms
Alkem Laboratories Days Payable Historical Data
* Premium members only.
The historical data trend for Alkem Laboratories's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Alkem Laboratories's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alkem Laboratories Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Alkem Laboratories's Days Payable distribution charts can be found below:
* The bar in red indicates where Alkem Laboratories's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Alkem Laboratories's Days Payable for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alkem Laboratories (NSE:ALKEM) has a Days Payable of 164.10 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Alkem Laboratories and its competitors. This is 57% above median its historical median of 104.66. Over the past decade, Alkem Laboratories' Days Payable has ranged from 85.65 to 146.33. According to the industry distribution chart, Alkem Laboratories ranks #254 out of 922 companies in the Drug Manufacturers industry, placing it in the top 27.5%.
Is Alkem Laboratories' Days Payable too high?
Alkem Laboratories' current Days Payable of 164.10 is 57% above median its 10-year median of 104.66. Over the past 10 years, this metric has ranged from a low of 85.65 to a high of 146.33. The Drug Manufacturers industry median Days Payable is 90.84. Alkem Laboratories' value of 164.10 is 80.7% above this industry median. Based on the distribution chart, Alkem Laboratories ranks #254 out of 922 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Alkem Laboratories has a GF Score™ of 96/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Alkem Laboratories' Days Payable compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Alkem Laboratories ranks #254 out of 922 companies for Days Payable. This puts Alkem Laboratories in the upper half of its industry. The industry median Days Payable is 90.84. Alkem Laboratories' value of 164.10 is 80.7% above this benchmark. Historically, Alkem Laboratories' own Days Payable has ranged from 85.65 to 146.33 over the past decade. While the company's 10-year median is 104.66 vs. the industry median of 90.84, Alkem Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.84, based on 922 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alkem Laboratories's current Days Payable of 164.10 is 80.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Alkem Laboratories and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alkem Laboratories's current Days Payable is 164.10, which is 57% above median its own 10-year median of 104.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alkem Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Alkem Laboratories (NSE:ALKEM) is currently considered Fairly Valued. The stock's GF Value™ is ₹6,078.06, compared to a current price of ₹5,567.50 — trading 8.4% below its estimated fair value. The current Days Payable is 164.10, which is 57% above median its 10-year median of 104.66 and 80.7% above the Drug Manufacturers industry median of 90.84. Alkem Laboratories' overall GF Score™ is 96/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Alkem Laboratories (NSE:ALKEM), the current Days Payable is 164.10 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alkem Laboratories (NSE:ALKEM) Overvalued in 2026?
Based on GuruFocus' analysis, Alkem Laboratories stock appears to be undervalued.
The current stock price of ₹5,567.50 is trading 8.4% below its estimated GF Value™ of ₹6,078.06.
GuruFocus considers Alkem Laboratories to be Fairly Valued.
Key valuation signals for NSE:ALKEM:
Days Payable: 164.10 (57% above median its 10-year median of 104.66)
GF Value™: ₹6,078.06 vs. price of ₹5,567.50 (8.4% below fair value)
Industry Position: 80.7% above the Drug Manufacturers median (#254 of 922)
No single metric tells the full story. See the NSE:ALKEM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alkem Laboratories Ltd is an Indian pharmaceutical company engaged in the development, manufacture, and sale of pharmaceutical and nutraceutical products. The company produces branded generics, generic drugs, active pharmaceutical ingredients (APIs) and nutraceuticals in acute and chronic therapeutic areas, such as anti-infective, pain and analgesics, vitamins/minerals/nutrients, cardiac and Diabetology, Gynecology, neuro/central nervous system, dermatology, anti-diabetes, anti-osteoporosis, cardiovascular, and muscle relaxants, which are marketed in Indian and International markets. It operates through the pharmaceutical business segment.
96GF Score
Get the complete analysis for NSE:ALKEM
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:ALKEM has been successfully added to your 
